Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Top Analyst Reports for Mastercard, UnitedHealth & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), UnitedHealth Group (UNH) and Merck (MRK).
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results.
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
by Zacks Equity Research
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo
Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.
Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.
Stock Market News For Oct 30, 2019
by Zacks Equity Research
Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Strong Q3 Earnings Data Deluge
by Zacks Equity Research
Strong Q3 Earnings Data Deluge
Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in third-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.
Q3 Earnings Bonanza: GM, MRK, MA & More
by Mark Vickery
GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.
Merck (MRK) Q3 Earnings and Revenues Surpass Estimates (Revised)
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 20.80% and 5.96%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Tops Q3 Earnings Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 20.80% and -99.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Why Earnings Season Could Be Great for Merck (MRK)
by Zacks Equity Research
Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks Value Trader Highlights: Merck, Disney, Whitestone REIT, Gap and Wells Fargo
by Zacks Equity Research
Zacks Value Trader Highlights: Merck, Disney, Whitestone REIT, Gap and Wells Fargo
Lessons on How to Build a Million Dollar Portfolio
by Tracey Ryniec
Anne Scheiber started with $5,000 and in the end her portfolio was worth $22 million. Here???s how she did it.